COMMUNIQUÉS West-GlobeNewswire

Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses
18/03/2024
The company announced the initiation of RAPIDe-3, the Phase 3 clinical trial evaluating the efficacy and safety of deucrictibant immediate-release capsule (PHVS416) for the treatment of HAE attacks ZUG, Switzerland, [...]
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 29 février 2024
18/03/2024
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 29 février 2024 En application de l'article L. 233-8 II du code de commerce et de l'article 222-12-5 du règlement général de l'AMF, [...]
Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer
18/03/2024
MALVERN, Pa., March 18, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and [...]
BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million Financing
18/03/2024
Acquisition creates leading phage therapy company with an advanced pipeline that includes two Phase 2 assets, BX004 for the treatment of chronic pulmonary infections in cystic fibrosis (“CF”) patients and BX211 for the [...]
Oculis Reports Q4 and Full Year 2023 Financial Results and Update on Company Progress
18/03/2024
A successful year including NASDAQ listing and positive results from two Phase 3 programs in OCS-01: Phase 3 Stage 1 DIAMOND trial for Diabetic Macular Edema (DME), and Phase 3 OPTIMIZE-1 trial for inflammation and pain [...]
CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies
18/03/2024
SINGAPORE, March 18, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to [...]
Completion of share buy-back program
18/03/2024
Company Announcement COPENHAGEN, Denmark; March 18, 2024 – Genmab A/S (Nasdaq: GMAB) announces that its share buy-back program has been completed on March 15, 2024 On February 14, 2024, Genmab announced the initiation [...]
OBI Pharma Announces Poster Presentations at the AACR 2024 Annual Meeting for OBI-992 and GlycOBI™ ADC platform
18/03/2024
Poster Presentations to highlight the latest research on OBI-992 (anti-TROP2 ADC) and OBI’s novel GlycOBI ADC platform TAIPEI, Taiwan, March 18, 2024 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (TPEx: 4174) today announced [...]
SENISCA secures additional £3.7 million financing to support rapid development of senotherapeutic platform to treat age-related disease
18/03/2024
SENISCA secures additional £3.7 million financing to support rapid development of senotherapeutic platform to treat age-related disease £3.7 million seed financing supported by consortium of new and existing investors [...]
ONWARD® Medical Successfully Completes Benchmark Testing on Path to Commercialize ARC-EX® System
18/03/2024
Third-party tests from leading US lab confirm printed circuit board assembly (PCBA) conforms to prevailing international electrical standards, a requirement for commercial launch THIS PRESS RELEASE CONTAINS INSIDE [...]
Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMed
18/03/2024
Reimbursements deferred by 18 months to start in January 2026 instead of July 2024 Saint-Herblain (France), March 18, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced [...]
Valneva annonce un report de la date de début de remboursement du prêt contracté avec les sociétés Deerfield et OrbiMed
18/03/2024
Les remboursements sont différés de 18 mois et débuteront en janvier 2026 au lieu de juillet 2024 Saint-Herblain (France), le 18 mars 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les [...]
Idorsia and Viatris successfully close the transaction for the global research and development collaboration
18/03/2024
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – March 18, 2024 Idorsia Ltd (SIX: IDIA) today announced that it has successfully closed the transaction with Viatris Inc. (NASDAQ: VTRS), a global [...]
Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand
18/03/2024
Agreement pairs Norgine’s commercial expertise and leading European footprint with PEDMARQSI ® , the first and only approved therapy in the European Union and U.K. for reducing the risk of cisplatin-induced hearing loss [...]
Financière de Tubize - Annual report 2023
16/03/2024
FINANCIERE DE TUBIZE SA/NV Allée de la Recherche 60, 1070 Brussels Contact: investorrelations@financiere-tubize.be Annual Report 2023 Regulated information 16 March 2024 The board of directors of Financière de Tubize [...]
Financière de Tubize - Rapport annuel 2023
16/03/2024
FINANCIERE DE TUBIZE SA Allée de la Recherche 60, 1070 Bruxelles Contact: investorrelations@financiere-tubize.be Rapport annuel 2023 Information réglementée 16 mars 2024 Le conseil d’administration de la Financière de [...]
ProSomnus Reschedules Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call
16/03/2024
PLEASANTON, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA ) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced today it has postponed the release of its [...]
Ibogaine By David Dardashti Leverages Albert Einstein’s Corelation Between Photon Particles and Quantum Electrodynamics
16/03/2024
Ibogaine By David Dardashti Revolutionizes Solar Energy Efficiency Through Radiation Generators MIAMI, March 15, 2024 (GLOBE NEWSWIRE) -- Ibogaine By David Dardashti, a cutting-edge clinic driven by developing [...]
Psyence Biomedical Ltd. Receives Nasdaq Notifications Regarding Market Value of Listed Securities and Market Value of Publicly Held Shares
15/03/2024
NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (the “Company”) (Nasdaq: PBM) announced that on March 11, 2024, it received two letters from the listing qualifications department staff of The Nasdaq [...]

Pages